Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-069055
Filing Date
2024-08-14
Accepted
2024-08-14 16:21:28
Documents
73
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0210729-10q_cero.htm   iXBRL 10-Q 918540
2 CERTIFICATION ea021072901ex31-1_cero.htm EX-31.1 10735
3 CERTIFICATION ea021072901ex31-2_cero.htm EX-31.2 10630
4 CERTIFICATION ea021072901ex32-1_cero.htm EX-32.1 4075
5 CERTIFICATION ea021072901ex32-2_cero.htm EX-32.2 4174
  Complete submission text file 0001213900-24-069055.txt   5704683

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cero-20240630.xsd EX-101.SCH 61893
7 XBRL CALCULATION FILE cero-20240630_cal.xml EX-101.CAL 34790
8 XBRL DEFINITION FILE cero-20240630_def.xml EX-101.DEF 303209
9 XBRL LABEL FILE cero-20240630_lab.xml EX-101.LAB 505008
10 XBRL PRESENTATION FILE cero-20240630_pre.xml EX-101.PRE 301134
76 EXTRACTED XBRL INSTANCE DOCUMENT ea0210729-10q_cero_htm.xml XML 665942
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40877 | Film No.: 241208312
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)